Reminder of excerpted commentary re triplet trials from an earlier post on ASH2014:
Based on comments from ASCO2014, there was an expectation that another monoclonal antibody combined with Revlimid would read out at ASH2014 with the highly anticipated Phase III ELO-1 comparing Bristol-Myers Squibb/Abbvie’s Elotuzumab+Rd vs Rd in NDMM and ELO-2 in PTMM, however the required number of events have not been reached. The open label Phase II in PTMM had a 33 month PFS for ERd. However, the ASPIRE Phase III Kyprolis+Rd triplet vs Rd was presented with a PFS advantage of 26.3 months vs 17.6 months. During the Q&A at Celgene’s Analyst Event, there were questions about extended Duration of Therapy (DoTx) from triplets with Rd backbone being factored into guidance. JF said in the absence of triplet data, the assumptions were conservative. Now that ASPIRE data has been seen, they feel more and more comfortable with the positive impact on DoTx.